# A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

> **NCT00002208** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 400 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Lamivudine
- **DRUG:** Stavudine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00002208
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 400 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002208, "A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00002208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*